GLPG 3221

Drug Profile

GLPG 3221

Alternative Names: GLPG3221

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer Galapagos NV
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 21 Nov 2017 Phase-I clinical trials in Cystic fibrosis (In volunteers) in Belgium (PO)
  • 20 Jun 2017 Preclinical trials in Cystic fibrosis in Belgium (PO)
  • 20 Jun 2017 Galapagos plans a phase I trial for the triple combination comprising GLPG 3067, GLPG 2222 and GPLG 3221 for Cystic fibrosis in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top